Stay Up to Date
Breaking News,
Updates, & More
Click Here to

More Bad News for Erythropoiesis-Stimulating Agents in Chemotherapy-Induced Anemia

TOP - May 2015, Vol 8, No 2 - Breast Cancer

San Antonio, TX—Adding an erythropoiesis-stimulating agent (ESA) to best supportive care failed to demonstrate noninferiority for progression-free survival (PFS) compared with best supportive care alone in patients with metastatic breast cancer, in a clinical trial known as EPO-ANE-3010 that was requested by the FDA.

Standard care alone or in combination with epoetin alfa (Epogen; Procrit) resulted in a median PFS of 7.4 months, as defined by investigator-assessed progressive disease. A separate analysis based on independent review showed identical PFS of 7.6 months in the 2 treatment groups. Moreover, investigator-determined time to progression showed a troubling increase in the risk for disease progression in patients who received the ESA.

The findings bring to full circle the use of ESAs for the treatment of chemotherapy-induced anemia, which has gone from enthusiastic support to disappointment, said Brian Leyland-Jones, MD, PhD, a medical oncologist at the Avera Cancer Institute, Sioux Falls, SD, who presented the trial results at the 2014 San Antonio Breast Cancer Symposium.

“For the management of anemia in the first- or second-line chemotherapy treatment of metastatic breast cancer, transfusion would be the preferred approach,” said Dr Leyland-Jones. “If epoetin alfa is to be used in the more advanced settings of metastatic breast cancer, this should be done very cautiously, in limited circumstances, only after a careful assessment of risks and benefits for epoetin alfa and alternative treatments—transfusion, interruption or cessation of chemotherapy—and with the patient fully involved in the decision-making process.”

An ongoing randomized, phase 3 clinical trial of darbepoetin alpha (Aransep) versus best supportive care for anemia in platinum-treated non–small-cell lung cancer is expected to provide additional information about the benefit-risk profile of ESAs, Dr Leyland-­Jones added.

For more than a decade, concern has surrounded the use of ESAs in chemotherapy-related anemia. Two earlier studies of ESAs in metastatic breast cancer showed higher on-study mortality, no difference in time to progression, and a higher incidence of thrombotic events in patients who received ESAs. In 2004, the US Food and Drug Administration requested a trial to confirm findings from the EPO-INT-76 trial, which showed a 37% increased risk for on-study mortality in patients with metastatic breast cancer who received epoetin alfa but no difference in time to progression.

A principal investigator in the EPO-INT-76 trial, Dr Leyland-Jones presented the results from the new EPO-ANE-3010 trial, which was conducted at sites in 19 countries and enrolled 2098 patients receiving first- or second-line chemotherapy for metastatic breast cancer and a hemoglobin level of ≤11 g/dL.

The patients’ median age was 52 years; 25% of the patients had a body mass index of ≥30; 55% were postmenopausal; and the median hemoglobin level was 10.4 to 10.5 g/dL. Patients received a median of 8 doses of epoetin alfa, and the median weekly dose was 32,316.7 IU.

The overall survival was 17.2 months with epoetin alfa and 17.4 months with standard of care, a difference that did not meet criteria for noninferiority. The adverse event profiles were similar in the 2 treatment groups.

These results further question the use of ESAs in the treatment of anemia associated with chemotherapy.

Related Items
FDA Updates Mammography Regulations in MQSA Final Rule
TOP - May 2023 Vol 16, No 3 published on May 15, 2023 in Breast Cancer, Healthcare Policy
Pausing Endocrine Therapy to Become Pregnant Appears Safe for Women with Breast Cancer
Patricia Stewart
TOP - March 2023 Vol 16, No 2 published on March 14, 2023 in Breast Cancer, SABCS
Factors Associated with Greater Risk for Abemaciclib Discontinuation in Patients with Early-Stage Breast Cancer
William King
TOP - November 2022 Vol 15, No 6 published on November 9, 2022 in Breast Cancer
Radiation Therapy May Be Omitted for Some Older Women with Luminal A Breast Cancer
Patricia Stewart
TOP - November 2022 Vol 15, No 6 published on November 9, 2022 in Breast Cancer
Trastuzumab Deruxtecan Represents New Standard of Care for Patients with HER2-Low Metastatic Breast Cancer
William King
TOP - September 2022 Vol 15, No 5 published on September 15, 2022 in Breast Cancer
Pembrolizumab plus Chemotherapy Prolongs Survival in Patients with Triple-Negative Breast Cancer and PD-L1 Combined Positive Score ≥10
Patricia Stewart
TOP - March 2022 Vol 15, No 2 published on March 16, 2022 in SABCS, Breast Cancer
Trastuzumab Deruxtecan Beats Trastuzumab Emtansine as Second-Line Therapy for HER2-Positive Metastatic Breast Cancer
TOP - March 2022 Vol 15, No 2 published on March 16, 2022 in SABCS, Breast Cancer
Olaparib Extends Disease-Free Survival in Patients with Early-Stage Breast Cancer and BRCA Mutation
William King
TOP - November 2021 Vol 14, No 7 published on November 10, 2021 in Breast Cancer
Tucatinib plus Trastuzumab and Capecitabine Triplet Maintains Survival Benefit in HER2-Positive Metastatic Breast Cancer: Updated Results from HER2CLIMB Trial
Charlie Dawson
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Breast Cancer
Cryoablation Appears Safe and Effective in Low-Risk, Early-Stage Breast Cancer
William Ackerman
TOP - July 2021 Vol 14, No 4 published on July 20, 2021 in Breast Cancer
Last modified: July 22, 2021